GLP-1 Savings Cards in 2026: The Complete Cost-Cutting Guide

Without any coverage, Ozempic, Wegovy, Mounjaro, and Zepbound list at roughly $1,000 to $1,350 for a 28-day supply at retail pharmacies in 2026. Ozempic's wholesale acquisition cost is about $968 per month, Wegovy about $1,349, Mounjaro about $1,069, and Zepbound about $1,059 in pen form. But almost no one pays the list price.

What people actually pay falls into four buckets: $0–$25 with strong commercial coverage and a savings card; $349–$499 through Eli Lilly's self-pay vial program (LillyDirect Zepbound); $150–$400 for compounded semaglutide where still legally available; and $800–$1,200 for the unlucky middle who have either no coverage or insurance that explicitly excludes anti-obesity medications. The price you actually face depends almost entirely on what insurance label your prescription carries — diabetes versus obesity — and whether your plan formulary covers it.

A GLP-1 savings card is a manufacturer-funded coupon that lowers your copay at the pharmacy, on top of whatever your insurance already covers. Novo Nordisk runs cards for Ozempic, Wegovy, Rybelsus, and Saxenda. Eli Lilly runs cards for Mounjaro and Zepbound. The cards are not insurance — they are a coupon program the manufacturer pays for to lower the price you actually see at checkout.

The catch: savings cards almost always require commercial (employer or marketplace) insurance. If you have Medicare, Medicaid, TRICARE, or VA coverage, federal anti-kickback rules block you from using them. They also cap the total annual benefit — typically $1,800 to $4,800 per year depending on the drug. If your card hits its annual cap, your copay jumps back to whatever your plan charges.

All five major brand-name GLP-1s have some form of savings program in 2026. The specifics differ by manufacturer and by whether you have coverage. The table below shows the 2026 savings card terms for each — confirm current numbers on the manufacturer site before you fill, since these update quarterly.

Insurance coverage hinges almost entirely on the indication on your prescription. Type 2 diabetes is the easiest path: nearly every commercial plan and Medicare Part D plan covers Ozempic, Mounjaro, Rybelsus, and Trulicity for diabetes. Obesity is harder: most plans require prior authorization, a documented BMI of 30+ (or 27+ with a comorbidity), and proof you have tried lifestyle modification. About 40 percent of commercial plans cover Wegovy or Zepbound for weight loss in 2026, up from roughly 25 percent in 2023, as employers respond to demand and as long-term outcomes data accumulate.

Heart disease prevention is the newest covered indication. After the SELECT trial showed Wegovy reduces major cardiovascular events by 20 percent in people with established heart disease and obesity, the FDA expanded Wegovy's label in 2024, and many plans (and Medicare) now cover Wegovy specifically for this indication. If you have heart disease and a BMI of 27+, ask your cardiologist whether the SELECT criteria fit you — that may be your path to coverage. The [molecular and clinical differences](/blog/tirzepatide-vs-semaglutide-comparison-2026) between semaglutide and tirzepatide also matter for which prior authorization will go through fastest at your particular plan.

Compounded GLP-1s used to be the most common workaround for people without coverage, but the legal landscape changed dramatically in late 2024 and 2025. The FDA removed semaglutide and tirzepatide from the official drug shortage list as Novo Nordisk and Eli Lilly ramped up production. Once a drug is off the shortage list, 503A and 503B compounding pharmacies can no longer legally compound "essentially copies" of those brand medications for general dispensing.

What remains legal in 2026 is narrower: compounded versions for documented allergies to inactive ingredients, certain personalized dosing strengths, or formulations a clinician deems medically necessary. Many telehealth companies that built their business on $200–$300/month compounded semaglutide have either pivoted to brand prescriptions, oral GLP-1 alternatives, or shut down their compounding lines. If a telehealth company is still offering compounded semaglutide for under $300 with no questions asked, treat that as a yellow flag — verify the pharmacy is a registered 503A or 503B facility, confirm the source of their active pharmaceutical ingredient, and ask exactly which clinical justification they are using.

Yes — both FSA and HSA dollars cover GLP-1 medications when prescribed for an FDA-approved indication. That means Ozempic for diabetes, Wegovy or Zepbound for obesity meeting the BMI criteria, Wegovy for cardiovascular prevention, or Saxenda for chronic weight management. You will need either a doctor's prescription on file or, in some cases, a letter of medical necessity that documents the diagnosis.

The practical play: if your employer offers an FSA, project your annual GLP-1 out-of-pocket (copays plus any non-covered months) and contribute that amount pre-tax. For someone paying $25/month with a savings card, that is $300/year — modest savings. For someone paying $499/month self-pay through LillyDirect, FSA contributions of $5,988 could save $1,500+ in taxes depending on your marginal rate. HSA dollars roll over year to year, so they are even more flexible if you have a high-deductible plan.

Medicare coverage in 2026 still falls along the same line: yes for diabetes, yes for heart disease prevention (Wegovy only), no for obesity alone. The 2003 statutory exclusion that bars Medicare Part D from covering anti-obesity drugs is still in place, despite ongoing legislative efforts to repeal it. The CMS coverage expansion proposed in late 2024 was withdrawn in early 2025, leaving the landscape essentially unchanged for older Americans seeking GLP-1s for weight loss alone.

What changed in 2024 and remains true in 2026 is the cardiovascular indication. Medicare Part D plans now cover Wegovy for people with established cardiovascular disease and a BMI of 27 or higher, based on the SELECT trial criteria. If you are on Medicare and have had a heart attack, stroke, or have established coronary disease plus excess weight, ask your cardiologist about a SELECT-criteria prescription. For long-term planning, see our piece on [long-term maintenance doses](/blog/glp-1-maintenance-dose-long-term-sweet-spot) — Medicare-eligible patients especially need to plan for what coverage looks like at the maintenance phase.

The cheapest path depends on your insurance. If you have commercial coverage that covers the drug, the answer is the manufacturer savings card — $25/month or less. If you do not have coverage, the cheapest legitimate brand option is LillyDirect's Zepbound self-pay vial program at $349 for the 2.5 mg dose and $499 for 5 mg or 10 mg, billed monthly. For people who started on Wegovy and want to switch for cost reasons, our guide to [switching from Wegovy to Zepbound](/blog/switching-from-wegovy-to-zepbound-when-and-how) covers the clinical and logistical considerations.

If you are paying out of pocket and Zepbound vials are not a fit, the next-cheapest option in 2026 is Rybelsus — Novo Nordisk's oral semaglutide — which often runs $300–$500/month with various savings programs, even without ideal coverage. The trade-off is that the oral form produces less weight loss than injectable semaglutide (about 4–5 percent of body weight versus 15 percent for Wegovy).